Publications

5600 Results

Long term consequences of intermittent and continuous androgen deprivation in patients with metastatic prostate cancer

Authors
D Hershman;JM Unger;J Wright;S Ramsey;C Till;C Tangen;W Barlow;C Blanke;IM Thompson;M Hussain
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 5008); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;
Year
2015
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346

Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine

Authors
A Denicoff;G Schroer;H Massett;R Bangs;J Berlin;M Bischoff;F Desanto;A Duli;S Hartson-Stine;E Horvath;R Lambersky;M Katz;S Ramalingam;W Williams;N Seibel;W McCaskill-Stevens;M Mooney;J Abrams
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr LBA500); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Cancer Care Delivery

Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance).

Authors
PP Singh;Q Shi;N Foster;A Grothey;A Shields;FA Sinicrope;DJ Sargent;SR Alberts
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 3531); American Society of Clinical Oncology Annual Meeting (May 29-June 2,2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N0147

Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405

Authors
D Schrag;A Dueck;M Naughton;D Niedzwiecki;C Earle;J Shaw;A Grothey;H Hochster;C Blanke;A Venook
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 6504); American Society of Clinical Oncology Annual Meeting (May 29-June 2,2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Randomized phase II study of everolimus alone (E) versus everolimus plus bevacizumab (E+B) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors, CALGB 80701

Authors
M Kulke;D Niedzwiecki;N Foster;B Fruth;H Kennecke;E Wolin;A Venook
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4005); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80701

ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer

Authors
DE Gerber;GR Oxnard;SJ Mandrekar;S Dahlberg;S Malik;M Mooney;J Abrams;P Janne;T Li;S Ramalingam;E Vokes;R Govindan
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS7583); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Lung
Study Number(s)
CTSU/E4512

Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity

Authors
M Zlobinsky Rubinstein;RJ Gray;J Sparano;J Zujewski;T Whelan;KS Albain;D Hayes;CE Geyer;EC Dees;EA Perez;M Keane;C Vallejos;T Goggins;I Mayer;A Brufsky;D Toppmeyer;V Kaklamani;J Atkins;J Berenberg;J Sledge
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 533); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Breast

Impact of neoadjuvant therapy on breast conservation rates in triple- negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance)

Authors
M Golshan;C Cirrincione;D Berry;L Carey;W Sikov;N Henry;G Somlo;E Port;E Winer;C Hudis;D Ollila
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 1007); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Breast
Study Number(s)
CTSU/C40603

Lung Master Protocol (Lung-MAP) biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400

Authors
R Herbst;D Gandara;F Hirsch;M Redman;M LeBlanc;PC Mack;L Schwartz;E Vokes;S Ramalingam;JD Bradley;D Sparks;H Zhou;C Miwa;VA Miller;R Yelensky;Y Li;JD Allen;EV Sigal;D Wholley;CC Sigman;G Blumenthal;S Malik;G Kelloff;J Abrams;C Blanke;V Papadimitrakopoulou
Journal / Conference
Clinical Cancer Research, Apr 1;21(7):1514-1524
Year
2015
Research Committee(s)
Lung
PMID
PMID25680375
PMC
PMC4654466
Study Number(s)
S1400

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

Authors
R Khan;MV Dhodapkar;A Rosenthal;C Heuck;X Papanikolaou;P Qu;F van Rhee;M Zangari;Y Jethava;J Epstein;S Yaccoby;J Crowley;N Petty;C Bailey;G Morgan;B Barlogie
Journal / Conference
Haematologica Sep;100(9):1214-1221
Year
2015
Research Committee(s)
Myeloma
PMID
PMID26022710
PMC
PMC4800692
Study Number(s)
S0120